Gujarat Themis Biosyn: Sachin D. Patel Acquires 5.23 Lakh Shares Worth ₹19.99 Crore
Sachin D. Patel acquired 5,23,560 shares of Gujarat Themis Biosyn Limited on July 30, 2026, for ₹19.99 crore at ₹382 per share. This inter-se promoter transfer increased his stake to 2.77%. The acquisition is exempt from open offer requirements under SEBI Takeover Regulations.
The transaction involves an inter-se transfer of shares within the promoter group and does not represent a change in control or a significant dilution/consolidation of the promoter's stake. The percentage change in shareholding is relatively small.
The announcement pertains to an inter-se transfer of shares among promoters, which is a routine regulatory filing and does not inherently indicate a positive or negative development for the company's business operations or financial performance.
Gujarat Themis Biosyn Limited has received disclosures regarding an acquisition of shares under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Sachin D. Patel acquired 5,23,560 equity shares of the company on July 30, 2026.
This acquisition represents 0.48% of the total diluted share capital of Gujarat Themis Biosyn Limited. The shares were acquired at a price of ₹382 per share, amounting to a total transaction value of approximately ₹19.99 crore. The acquisition was an inter-se transfer among the promoter and promoter group, specifically from Pharmaceutical Business Group India Limited to Sachin D. Patel.
This transaction falls under Regulation 10(1)(a)(i I) of the SAST Regulations, exempting the acquirer from making an open offer as the transfer is among persons named as promoters in the company's shareholding pattern. Prior intimation of this inter-se transfer was made on July 14, 2026, and the disclosure to the stock exchanges was made four working days prior to the transaction date as required under Regulation 10(5).
Following the transaction, Sachin D. Patel's shareholding in Gujarat Themis Biosyn Limited increased from 2.29% (24,97,200 shares) to 2.77% (30,20,760 shares). Concurrently, Pharmaceutical Business Group India Limited's shareholding decreased from 47.02% (5,12,40,000 shares) to 46.54% (5,07,16,440 shares). The disclosure was made by Sachin D. Patel on August 4, 2026.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.